China's Biotech Industry
- Thread starter supercat
- Start date
Ningbo Synsense has collaborated with Zurich Institute of Neuroinformatics to release a new generation of ultra-low-power, high-throughput invasive brain-computer interface chip solution. It overcomes the challenges of high-density neural signal acquisition and real-time processing, improving energy efficiency by 10 to 100 times compared to existing solutions, providing fundamental support for the large-scale application of brain-computer interfaces worldwide.
here is their home page
looks like Ningbo is just a branch and they are based in Zurich
supercat
Colonel
Harnessing the energy from blinking and controlling devices using eye movement:
There are many strains of E. Coli. Some of them are innocuous. Chinese scientists have bio-engineered a strain of such harmless E. Coli to treat inflammatory bowel disease.
Financial Times talks about China's biotech industry:
There are many strains of E. Coli. Some of them are innocuous. Chinese scientists have bio-engineered a strain of such harmless E. Coli to treat inflammatory bowel disease.
Financial Times talks about China's biotech industry:
Dongfang Electric along with China Institute of Atomic Energy have developed and built reactor vessel for world's highest power solution-type medical isotope experimental reactor, which is needed for diagnosis and treatment of major diseases such as cardiovascular and cerebrovascular diseases, malignant tumors, and neurodegenerative diseases
BEIJING, Jan. 27 (Xinhua) -- Ribevirtamaab injection, developed by a Chinese company, recently received conditional approval from the National Medical Products Administration for marketing in the treatment of adult patients with chronic hepatitis D virus infection, with or without compensated cirrhosis. Ribevirtamaab represents a breakthrough in the treatment of viral hepatitis and is the first antibody drug approved in this field.
On February 4th, reporters learned from Xijing Hospital of Air Force Medical University that Academician Dou Kefeng's team, in collaboration with the First Affiliated Hospital of Sun Yat-sen University, Tangdu Hospital of Air Force Medical University, and Sichuan Zhongke Aoge Biotechnology Co., Ltd., successfully performed the world's first in vitro perfusion therapy of six-gene-edited pig liver on a patient with liver failure. After 66 hours of continuous treatment, the patient's condition improved significantly, with major liver function indicators showing marked improvement. A technology novelty search confirmed that this is the first report of its kind both domestically and internationally.
China's biotech pipeline is just something else.
HengRui is quite the beast and they have such a long pipeline of drug development.